These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1667 related articles for article (PubMed ID: 24398428)

  • 1. Overcoming acquired BRAF inhibitor resistance in melanoma via targeted inhibition of Hsp90 with ganetespib.
    Acquaviva J; Smith DL; Jimenez JP; Zhang C; Sequeira M; He S; Sang J; Bates RC; Proia DA
    Mol Cancer Ther; 2014 Feb; 13(2):353-63. PubMed ID: 24398428
    [TBL] [Abstract][Full Text] [Related]  

  • 2. p53 Reactivation by PRIMA-1(Met) (APR-246) sensitises (V600E/K)BRAF melanoma to vemurafenib.
    Krayem M; Journe F; Wiedig M; Morandini R; Najem A; Salès F; van Kempen LC; Sibille C; Awada A; Marine JC; Ghanem G
    Eur J Cancer; 2016 Mar; 55():98-110. PubMed ID: 26790143
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The HSP90 inhibitor XL888 overcomes BRAF inhibitor resistance mediated through diverse mechanisms.
    Paraiso KH; Haarberg HE; Wood E; Rebecca VW; Chen YA; Xiang Y; Ribas A; Lo RS; Weber JS; Sondak VK; John JK; Sarnaik AA; Koomen JM; Smalley KS
    Clin Cancer Res; 2012 May; 18(9):2502-14. PubMed ID: 22351686
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mitogen-activated protein kinase (MAPK) hyperactivation and enhanced NRAS expression drive acquired vemurafenib resistance in V600E BRAF melanoma cells.
    Lidsky M; Antoun G; Speicher P; Adams B; Turley R; Augustine C; Tyler D; Ali-Osman F
    J Biol Chem; 2014 Oct; 289(40):27714-26. PubMed ID: 25063807
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antitumor activity of BRAF inhibitor vemurafenib in preclinical models of BRAF-mutant colorectal cancer.
    Yang H; Higgins B; Kolinsky K; Packman K; Bradley WD; Lee RJ; Schostack K; Simcox ME; Kopetz S; Heimbrook D; Lestini B; Bollag G; Su F
    Cancer Res; 2012 Feb; 72(3):779-89. PubMed ID: 22180495
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reversing melanoma cross-resistance to BRAF and MEK inhibitors by co-targeting the AKT/mTOR pathway.
    Atefi M; von Euw E; Attar N; Ng C; Chu C; Guo D; Nazarian R; Chmielowski B; Glaspy JA; Comin-Anduix B; Mischel PS; Lo RS; Ribas A
    PLoS One; 2011; 6(12):e28973. PubMed ID: 22194965
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Novel ATP-Competitive MEK/Aurora Kinase Inhibitor BI-847325 Overcomes Acquired BRAF Inhibitor Resistance through Suppression of Mcl-1 and MEK Expression.
    Phadke MS; Sini P; Smalley KS
    Mol Cancer Ther; 2015 Jun; 14(6):1354-64. PubMed ID: 25873592
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Modelling vemurafenib resistance in melanoma reveals a strategy to forestall drug resistance.
    Das Thakur M; Salangsang F; Landman AS; Sellers WR; Pryer NK; Levesque MP; Dummer R; McMahon M; Stuart DD
    Nature; 2013 Feb; 494(7436):251-5. PubMed ID: 23302800
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The MEK1/2 Inhibitor AZD6244 Sensitizes BRAF-Mutant Thyroid Cancer to Vemurafenib.
    Song H; Zhang J; Ning L; Zhang H; Chen D; Jiao X; Zhang K
    Med Sci Monit; 2018 May; 24():3002-3010. PubMed ID: 29737325
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Resistance to selective BRAF inhibition can be mediated by modest upstream pathway activation.
    Su F; Bradley WD; Wang Q; Yang H; Xu L; Higgins B; Kolinsky K; Packman K; Kim MJ; Trunzer K; Lee RJ; Schostack K; Carter J; Albert T; Germer S; Rosinski J; Martin M; Simcox ME; Lestini B; Heimbrook D; Bollag G
    Cancer Res; 2012 Feb; 72(4):969-78. PubMed ID: 22205714
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combination of antibodies directed against different ErbB3 surface epitopes prevents the establishment of resistance to BRAF/MEK inhibitors in melanoma.
    Fattore L; Malpicci D; Marra E; Belleudi F; Noto A; De Vitis C; Pisanu ME; Coluccia P; Camerlingo R; Roscilli G; Ribas A; Di Napoli A; Torrisi MR; Aurisicchio L; Ascierto PA; Mancini R; Ciliberto G
    Oncotarget; 2015 Sep; 6(28):24823-41. PubMed ID: 26208478
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The HSP90 inhibitor ganetespib potentiates the antitumor activity of EGFR tyrosine kinase inhibition in mutant and wild-type non-small cell lung cancer.
    Smith DL; Acquaviva J; Sequeira M; Jimenez JP; Zhang C; Sang J; Bates RC; Proia DA
    Target Oncol; 2015 Jun; 10(2):235-45. PubMed ID: 25077897
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Molecular pathways: adaptive kinome reprogramming in response to targeted inhibition of the BRAF-MEK-ERK pathway in cancer.
    Johnson GL; Stuhlmiller TJ; Angus SP; Zawistowski JS; Graves LM
    Clin Cancer Res; 2014 May; 20(10):2516-22. PubMed ID: 24664307
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combinatorial treatments that overcome PDGFRβ-driven resistance of melanoma cells to V600EB-RAF inhibition.
    Shi H; Kong X; Ribas A; Lo RS
    Cancer Res; 2011 Aug; 71(15):5067-74. PubMed ID: 21803746
    [TBL] [Abstract][Full Text] [Related]  

  • 15. COT drives resistance to RAF inhibition through MAP kinase pathway reactivation.
    Johannessen CM; Boehm JS; Kim SY; Thomas SR; Wardwell L; Johnson LA; Emery CM; Stransky N; Cogdill AP; Barretina J; Caponigro G; Hieronymus H; Murray RR; Salehi-Ashtiani K; Hill DE; Vidal M; Zhao JJ; Yang X; Alkan O; Kim S; Harris JL; Wilson CJ; Myer VE; Finan PM; Root DE; Roberts TM; Golub T; Flaherty KT; Dummer R; Weber BL; Sellers WR; Schlegel R; Wargo JA; Hahn WC; Garraway LA
    Nature; 2010 Dec; 468(7326):968-72. PubMed ID: 21107320
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The BRAF(V600E) inhibitor, PLX4032, increases type I collagen synthesis in melanoma cells.
    Jenkins MH; Croteau W; Mullins DW; Brinckerhoff CE
    Matrix Biol; 2015 Oct; 48():66-77. PubMed ID: 25989506
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation.
    Nazarian R; Shi H; Wang Q; Kong X; Koya RC; Lee H; Chen Z; Lee MK; Attar N; Sazegar H; Chodon T; Nelson SF; McArthur G; Sosman JA; Ribas A; Lo RS
    Nature; 2010 Dec; 468(7326):973-7. PubMed ID: 21107323
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The RAF inhibitor PLX4032 inhibits ERK signaling and tumor cell proliferation in a V600E BRAF-selective manner.
    Joseph EW; Pratilas CA; Poulikakos PI; Tadi M; Wang W; Taylor BS; Halilovic E; Persaud Y; Xing F; Viale A; Tsai J; Chapman PB; Bollag G; Solit DB; Rosen N
    Proc Natl Acad Sci U S A; 2010 Aug; 107(33):14903-8. PubMed ID: 20668238
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A new water soluble MAPK activator exerts antitumor activity in melanoma cells resistant to the BRAF inhibitor vemurafenib.
    Graziani G; Artuso S; De Luca A; Muzi A; Rotili D; Scimeca M; Atzori MG; Ceci C; Mai A; Leonetti C; Levati L; Bonanno E; Tentori L; Caccuri AM
    Biochem Pharmacol; 2015 May; 95(1):16-27. PubMed ID: 25795251
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    Sanchez IM; Purwin TJ; Chervoneva I; Erkes DA; Nguyen MQ; Davies MA; Nathanson KL; Kemper K; Peeper DS; Aplin AE
    Mol Cancer Ther; 2019 Sep; 18(9):1637-1648. PubMed ID: 31270153
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 84.